Originally published by our sister publication Clinical Oncology News
Updated with additional details on March 7.
By Clinical Oncology News Staff
The FDA approved the first interchangeable biosimilar to Prolia (denosumab) and Xgeva (denosumab). Sandoz’s Wyost (denosumab-bbdz) is an interchangeable biosimilar to U.S.-licensed Xgeva for the treatment of bone complications from cancer. Sandoz’s Jubbonti (denosumab-bbdz) is an interchangeable biosimilar to U.S.-licensed Prolia for the